CD40-mediated death and cytokine secretion in colorectal cancer: A potential target for inflammatory tumour cell killing

International Journal of Cancer

Volumn 121, Issue 6, 2007, Pages 1373-1381

  Georgopoulos, Nikolaos T ^a,b   Merrick, Alison ^a   Scott, Nigel ^a   Selby, Peter J ^a   Melcher, Alan ^a   Trejdosiewicz, Ludwik K ^a  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF YORK   (United Kingdom)

Author keywords

Apoptosis; CD40; Colorectal cancer; Human; Inflammatory cytokines

Indexed keywords

CD40 ANTIGEN; CD40 LIGAND; CYTOKINE; DNA FRAGMENT; LIPOCORTIN 5; PROPIDIUM IODIDE;

ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CANCER IMMUNOLOGY; COCULTURE; COLORECTAL CANCER; CONTROLLED STUDY; CYTOKINE RELEASE; FIBROBLAST CULTURE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; PRIORITY JOURNAL;

ANTIGENS, CD40; APOPTOSIS; CD40 LIGAND; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; CYTOKINES; FLOW CYTOMETRY; HUMANS; IMMUNOHISTOCHEMISTRY; INFLAMMATION;

EID: 34548084865     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.22846     Document Type: Article

References (51)

1. van Kooten C, Banchereau J. CD40-CD40 ligand. J Leukoc Biol 2000; 67:2-17.
2. Koho H, Paulie S, Ben-Aissa H, Jonsdottir I, Hansson Y, Lundblad ML, Perlmann P. Monoclonal antibodies to antigens associated with transitional cell carcinoma of the human urinary bladder. I. Determination of the selectivity of six antibodies by cell ELISA and immunofluorescence. Cancer Immunol Immunother 1984;17:165-72.
3. Dallman C, Johnson PW, Packham G. Differential regulation of cell survival by CD40. Apoptosis 2003;8:45-53.
4. Hess S, Rensing-Ehl A, Schwabe R, Buffer P, Engelmann H. CD40 function in nonhematopoietic cells. Nuclear factor κB mobilization and induction of IL-6 production. J Immunol 1995;155:4588-95.
5. Inui S, Kaisho T, Kikutani H, Stamenkovic I, Seed B, Clark EA, Kishimoto T. Identification of the intracytoplasmic region essential for signal transduction through a B cell activation molecule, CD40. Eur J Immunol 1990;20:1747-53.
6. Young LS, Eliopoulos AG. TNF receptors and their ligands: in sickness and in health, in life and death. Curr Opin Pharmacol 2004; 4:311-3.
7. Grell M, Douni E, Wajant H, Lohden M, Clauss M, Maxeiner B, Georgopoulos S, Lesslauer W, Kollias G, Pfizenmaier K, Scheurich P. The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell 1995; 83:793-802.
8. Bugajska U, Georgopoulos NT, Southgate J, Johnson PW, Graber P, Gordon J, Selby PJ, Trejdosiewicz LK. The effects of malignant transformation on susceptibility of human urothelial cells to CD40-mediated apoptosis. J Natl Cancer Inst 2002;94:1381-95.
9. Georgopoulos NT, Steele LP, Thomson MJ, Selby PJ, Southgate J, Trejdosiewicz LK. A novel mechanism of CD40-induced apoptosis of carcinoma cells involving TRAF3 and JNK/AP-1 activation. Cell Death Differ 2006;13:1789-801.
10. Maerten P, Liu Z, Ceuppens JL. Targeting of costimulatory molecules as a therapeutic approach in inflammatory bowel disease. BioDrugs 2003;17:395-411.
11. Gelbmann CM, Leeb SN, Vogl D, Maendel M, Herfarth H, Scholmerich J, Falk W, Rogler G. Inducible CD40 expression mediates NF κB activation and cytokine secretion in human colonic fibroblasts. Gut 2003;52:1448-56.
12. Vogel JD, West GA, Danese S, De La Motte C, Phillips MH, Strong SA, Willis J, Fiocchi C. CD40-mediated immune-nonimmune cell interactions induce mucosal fibroblast chemokines leading to T-cell transmigration. Gastroenterology 2004;126:63-80.
13. Cruickshank SM, McVay LD, Baumgart DC, Felsburg PJ, Carding SR. Colonic epithelial cell mediated suppression of CD4 T cell activation. Gut 2004;53:678-84.
14. Shaw NJ, Georgopoulos NT, Southgate J, Trejdosiewicz LK. Effects of loss of p53 and p16 function on life span and survival of human urothelial cells. Int J Cancer 2005;116:634-9.
15. Wingett DG, Vestal RE, Forcier K, Hadjokas N, Nielson CP. CD40 is functionally expressed on human breast carcinomas: variable inducibility by cytokines and enhancement of Fas-mediated apoptosis. Breast Cancer Res Treat 1998;50:27-36.
16. Hirano A, Longo DL, Taub DD, Ferris DK, Young LS, Eliopoulos AG, Agathanggelou A, Cullen N, Macartney J, Fanslow WC, Murphy WJ. Inhibition of human breast carcinoma growth by a soluble recombinant human CD40 ligand. Blood 1999;93:2999-3007.
17. Schwabe RF, Schnabl B, Kweon YO, Brenner DA. CD40 activates NF-κB and c-Jun N-terminal kinase and enhances chemokine secretion on activated human hepatic stellate cells. J Immunol 2001;166: 6812-19.
18. Eliopoulos AG, Dawson CW, Mosialos G, Floettmann JE, Rowe M, Armitage RJ, Dawson J, Zapata JM, Kerr DJ, Wakelam MJ, Reed JC, Kieff E, et al. CD40-induced growth inhibition in epithelial cells is mimicked by Epstein-Barr Virus-encoded LMP1: involvement of TRAF3 as a common mediator. Oncogene 1996;13:2243-54.
19. Eliopoulos AG, Davies C, Knox PG, Gallagher NJ, Afford SC, Adams DH, Young LS. CD40 induces apoptosis in carcinoma cells through activation of cytotoxic ligands of the tumor necrosis factor superfamily. Mol Cell Biol 2000;20:5503-15.
20. Pound JD, Challa A, Holder MJ, Armitage RJ, Dower SK, Fanslow WC, Kikutani H, Paulie S, Gregory CD, Gordon J. Minimal crosslinking and epitope requirements for CD40-dependent suppression of apoptosis contrast with those for promotion of the cell cycle and homotypic adhesions in human B cells. Int Immunol 1999;11:11-20.
21. Hess S, Engelmann H. A novel function of CD40: induction of cell death in transformed cells. J Exp Med 1996;183:159-67.
22. Wilson CA, Browning JL. Death of HT29 adenocarcinoma cells induced by TNF family receptor activation is caspase-independent and displays features of both apoptosis and necrosis. Cell Death Differ 2002;9:1321-33.
23. Steele LP, Georgopoulos NT, Southgate J, Selby PJ, Trejdosiewicz LK. Differential susceptibility to TRAIL of normal versus malignant human urothelial cells. Cell Death Differ 2006;13:1564-76.
24. Eliopoulos AG, Stack M, Dawson CW, Kaye KM, Hodgkin L, Sihota S, Rowe M, Young LS. Epstein-Barr virus-encoded LMP1 and CD40 mediate IL-6 production in epithelial cells via an NF-κB pathway involving TNF receptor-associated factors. Oncogene 1997;14:2899-916.
25. Altenburg A, Baldus SE, Smola H, Pfister H, Hess S. CD40 ligand-CD40 interaction induces chemokines in cervical carcinoma cells in synergism with IFN-gamma. J Immunol 1999;162:4140-7.
26. Gallagher NJ, Eliopoulos AG, Agathangelo A, Oates J, Crocker J, Young LS. CD40 activation in epithelial ovarian carcinoma cells modulates growth, apoptosis, and cytokine secretion. Mol Pathol 2002;55:110-20.
27. Hill SC, Youde SJ, Man S, Teale GR, Baxendale AJ, Hislop A, Davies CC, Luesley DM, Blom AM, Rickinson AB, Young LS, Eliopoulos AG. Activation of CD40 in cervical carcinoma cells facilitates CTL responses and augments chemotherapy-induced apoptosis. J Immunol 2005;174:41-50.
28. Davies CC, Mason J, Wakelam MJ, Young LS, Eliopoulos AG. Inhibition of phosphatidylinositol 3-kinase- and ERK MAPK-regulated protein synthesis reveals the pro-apoptotic properties of CD40 ligation in carcinoma cells. J Biol Chem 2004;279:1010-19.
29. Alexandroff AB, Jackson AM, Paterson T, Haley JL, Ross JA, Longo DL, Murphy WJ, James K, Taub DD. Role for CD40-CD40 ligand interactions in the immune response to solid tumours. Mol Immunol 2000;37:515-26.
30. Cao W, Cavacini LA, Tillman KC, Posner MR. CD40 function in squamous cell cancer of the head and neck. Oral Oncol 2005;41: 462-9.
31. Martinez FO, Sironi M, Vecchi A, Colotta F, Mantovani A, Locati M. IL-8 induces a specific transcriptional profile in human neutrophils: synergism with LPS for IL-1 production. Eur J Immunol 2004; 34:2286-92.
32. Shinohara H, Yano S, Bucana CD, Fidler IJ. Induction of chemokine secretion and enhancement of contact-dependent macrophage cytotoxicity by engineered expression of granulocyte-macrophage colony-stimulating factor in human colon cancer cells. J Immunol 2000;164:2728-37.
33. Kielian T, Nagai E, Ikubo A, Rasmussen CA, Suzuki T. Granulocyte/ macrophage-colony-stimulating factor released by adenovirally transduced CT26 cells leads to the local expression of macrophage inflammatory protein 1alpha and accumulation of dendritic cells at vaccination sites in vivo. Cancer Immunol Immunother 1999;48:123-31.
34. Tong AW, Seamour B, Chen J, Su D, Ordonez G, Frase L, Netto G, Stone MJ. CD40 ligand-induced apoptosis is Fas-independent in human multiple myeloma cells. Leuk Lymphoma 2000;36:543-58.
35. Baccam M, Woo SY, Vinson C, Bishop GA. CD40-mediated transcriptional regulation of the IL-6 gene in B lymphocytes: involvement of NF-κB, AP-1, and C/EBP. J Immunol 2003;170:3099-108.
36. Baccam M, Bishop GA. Membrane-bound CD154, but not CD40-specific antibody, mediates NF-κB-independent IL-6 production in B cells. Eur J Immunol 1999;29:3855-66.
37. Cagnoni F, Oddera S, Giron-Michel J, Riccio AM, Olsson S, Dellacasa P, Melioli G, Canonica GW, Azzarone B. CD40 on adult human airway epithelial cells: expression and proinflammatory effects. J Immunol 2004;172:3205-14.
38. Li H, Nord EP. CD40 ligation stimulates MCP-1 and IL-8 production, TRAF6 recruitment, and MAPK activation in proximal tubule cells. Am J Physiol Renal Physiol 2002;282:F1020-F1033.
39. Wang CY, Bassuk AG, Boise LH, Thompson CB, Bravo R, Leiden JM. Activation of the granulocyte-macrophage colony-stimulating factor promoter in T cells requires cooperative binding of Elf-1 and AP-1 transcription factors. Mol Cell Biol 1994;14:1153-9.
40. Cockerill PN, Bert AG, Jenkins F, Ryan GR, Shannon MF, Vadas MA. Human granulocyte-macrophage colony-stimulating factor enhancer function is associated with cooperative interactions between AP-1 and NFATp/c. Mol Cell Biol 1995;15:2071-9.
41. Johnson BV, Bert AG, Ryan GR, Condina A, Cockerill PN. Granulocyte-macrophage colony-stimulating factor enhancer activation requires cooperation between NFAT and AP-1 elements and is associated with extensive nucleosome reorganization. Mol Cell Biol 2004; 24:7914-30.
42. Baxendale AJ, Dawson CW, Stewart SE, Mudaliar V, Reynolds G, Gordon J, Murray PG, Young LS, Eliopoulos AG. Constitutive activation of the CD40 pathway promotes cell transformation and neoplastic growth. Oncogene 2005;24:7913-23.
43. Eliopoulos AG, Young LS. The role of the CD40 pathway in the pathogenesis and treatment of cancer. Curr Opin Pharmacol 2004; 4:360-7.
44. Cooke PW, James ND, Ganesan R, Wallace M, Burton A, Young LS. CD40 expression in bladder cancer. J Pathol 1999;188:38-43.
45. Palmer DH, Hussain SA, Ganesan R, Cooke PW, Wallace DM, Young LS, James ND. CD40 expression in prostate cancer: a potential diagnostic and therapeutic molecule. Oncol Rep 2004;12:679-82.
46. Kikuchi T, Crystal RG. Anti-tumor immunity induced by in vivo adenovirus vector-mediated expression of CD40 ligand in tumor cells. Hum Gene Ther 1999;10:1375-87.
47. Bronte V, Cingarlini S, Apolloni E, Serafini P, Marigo I, De Santo C, Macino B, Marin O, Zanovello P. Effective genetic vaccination with a widely shared endogenous retroviral tumor antigen requires CD40 stimulation during tumor rejection phase. J Immunol 2003;171:6396-405.
48. Loskog AS, Fransson ME, Totterman TT. AdCD40L gene therapy counteracts T regulatory cells and cures aggressive tumors in an orthotopic bladder cancer model. Clin Cancer Res 2005;11(24, Part 1):8816-21.
49. Ryschich E, Marten A, Schmidt E, Linnebacher M, Wentzensen N, Eisold S, Klar E, Buchler MW, Schmidt J. Activating anti-CD40 antibodies induce tumour invasion by cytotoxic T-lymphocytes and inhibition of tumour growth in experimental liver cancer. Eur J Cancer 2006;42:981-7.
50. Tong AW, Papayoti MH, Netto G, Armstrong DT, Ordonez G, Lawson JM, Stone MJ. Growth-inhibitory effects of CD40 ligand (CD154) and its endogenous expression in human breast cancer. Clin Cancer Res 2001;7:691-703.
51. Ghamande S, Hylander BL, Oflazoglu E, Lele S, Fanslow W, Repasky EA. Recombinant CD40 ligand therapy has significant antitumor effects on CD40-positive ovarian tumor xenografts grown in SCID mice and demonstrates an augmented effect with cisplatin. Cancer Res 2001;61:7556-62.